MARKET OUTLOOK
Growth hormone is an endogenous hormone produced by the pituitary gland; a deficiency in its production or activity is characterized by short stature, decreased capacity for exercise, and unfavorable changes in cardiovascular function. Avariety of recombinant human growth hormone (somatropin) brands are available to treat hypopituitarism, short stature, and rare genetic disorders. The choice of growth hormone product typically depends on the product’s delivery system and the support package offered by the manufacturer. This U.S. claims data analysis covers prescription patterns in growth hormone deficiency and other disorders for which recombinant growth hormone is approved for use.
QUESTIONS ANSWERED
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton
Key analysis provided: Brand/therapy usage across a longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flowcharts
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.